Key Points
- James Parsons, a director, bought 10,000 shares of Oncolytics Biotech on March 11 at an average price of $1.03, raising his direct holdings to 41,849 shares (a 31.4% increase); the purchase was disclosed in an SEC filing.
- ONCY trades near $1 with a market cap of about $104.45 million; analysts are mixed but the consensus is a "Moderate Buy" with an average target price of $8.50 and HC Wainwright recently boosting its target to $10.
Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) Director James Parsons acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was acquired at an average cost of $1.03 per share, for a total transaction of $10,300.00. Following the completion of the transaction, the director directly owned 41,849 shares in the company, valued at $43,104.47. This represents a 31.40% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Oncolytics Biotech Trading Up 2.3%
Shares of ONCY opened at $0.98 on Friday. The company has a market cap of $104.45 million, a price-to-earnings ratio of -3.51 and a beta of 0.92. The business's fifty day simple moving average is $1.01 and its two-hundred day simple moving average is $1.08. Oncolytics Biotech Inc. has a 12 month low of $0.33 and a 12 month high of $1.51.
Analyst Upgrades and Downgrades
ONCY has been the topic of several recent analyst reports. HC Wainwright increased their price objective on Oncolytics Biotech from $5.00 to $10.00 and gave the company a "buy" rating in a research report on Monday, November 17th. Wall Street Zen lowered Oncolytics Biotech from a "hold" rating to a "sell" rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $8.50.
View Our Latest Stock Analysis on ONCY
Institutional Investors Weigh In On Oncolytics Biotech
Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in Oncolytics Biotech in the 4th quarter worth $68,000. XTX Topco Ltd bought a new stake in Oncolytics Biotech during the fourth quarter valued at about $69,000. Tocqueville Asset Management L.P. bought a new stake in Oncolytics Biotech during the fourth quarter valued at about $63,000. CIBC Private Wealth Group LLC purchased a new stake in Oncolytics Biotech in the fourth quarter worth about $44,000. Finally, Citadel Advisors LLC purchased a new stake in Oncolytics Biotech in the third quarter worth about $535,000. 6.82% of the stock is currently owned by hedge funds and other institutional investors.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company's lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.
Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
